Inovio Pharmaceuticals Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Inovio Pharmaceuticals filed its Q1 2024 10-Q, detailing financial performance and a recent stock offering.</b>

AI Summary

INOVIO PHARMACEUTICALS, INC. (INO) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Inovio Pharmaceuticals, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing covers the first quarter of 2024. The company's principal executive offices are located at 6769 Mesa Ridge Rd., San Diego, CA 92121. Inovio Pharmaceuticals, Inc. was formerly known as Inovio Biomedical Corp and Genetronics Biomedical Corp. A subsequent event on April 18, 2024, involved an Underwritten Registered Direct Offering of common stock and warrants.

Why It Matters

For investors and stakeholders tracking INOVIO PHARMACEUTICALS, INC., this filing contains several important signals. This 10-Q filing provides investors with the latest financial and operational details for Inovio Pharmaceuticals, crucial for understanding the company's current standing and future prospects. The inclusion of a subsequent event regarding a stock and warrant offering on April 18, 2024, indicates potential capital raising activities and dilution considerations for shareholders.

Risk Assessment

Risk Level: medium — INOVIO PHARMACEUTICALS, INC. shows moderate risk based on this filing. The company's financial health and operational progress are subject to the inherent risks of the biotechnology industry, including clinical trial outcomes and regulatory approvals, which are not detailed in this header information but are typical for such filings.

Analyst Insight

Investors should review the full 10-Q filing to assess Inovio's financial performance, cash burn rate, and the implications of the recent stock and warrant offering.

Key Numbers

• 2024-03-31 — Period End Date (Conformed Period of Report)
• 2024-05-13 — Filing Date (Filed As Of Date)
• 2024-04-18 — Offering Date (Subsequent Event Date)

Key Players & Entities

• INOVIO PHARMACEUTICALS, INC. (company) — Filer name
• INO (company) — Ticker symbol
• 2024-03-31 (date) — Conformed period of report
• 2024-05-13 (date) — Filed as of date
• 6769 MESA RIDGE RD. (address) — Business street address
• SAN DIEGO (address) — Business city
• CA (address) — Business state
• 92121 (address) — Business zip code

FAQ

Industry Context

Inovio Pharmaceuticals operates in the biotechnology sector, focusing on the development of vaccines and therapies.

Regulatory Implications

As a publicly traded company, Inovio Pharmaceuticals is subject to SEC regulations and reporting requirements, including the filing of quarterly 10-Q reports.

What Investors Should Do

1. Analyze the detailed financial statements within the 10-Q to understand revenue, expenses, and cash flow.
2. Evaluate the terms and potential impact of the Underwritten Registered Direct Offering on share dilution and capital structure.
3. Review management's discussion and analysis (MD&A) for insights into operational progress and future outlook.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-13: Filing Date — Date the 10-Q report was officially filed with the SEC.
• 2024-04-18: Underwritten Registered Direct Offering — A significant subsequent event involving the issuance of stock and warrants.

Year-Over-Year Comparison

This filing is a 10-Q for the quarter ending March 31, 2024, providing updated financial information compared to previous filings.

Key Financial Figures

• $0.001 — ange on Which Registered COMMON STOCK, $0.001 PAR VALUE INO Nasdaq Capital Market I

Filing Documents

• ino-20240331.htm (10-Q) — 1085KB
• ino-33124x10qex311.htm (EX-31.1) — 9KB
• ino-3312410qex312.htm (EX-31.2) — 10KB
• ino-33124x10qex321.htm (EX-32.1) — 8KB
• ino-20240331_g1.jpg (GRAPHIC) — 449KB
• 0001055726-24-000020.txt (&nbsp;) — 6966KB
• ino-20240331.xsd (EX-101.SCH) — 41KB
• ino-20240331_cal.xml (EX-101.CAL) — 56KB
• ino-20240331_def.xml (EX-101.DEF) — 215KB
• ino-20240331_lab.xml (EX-101.LAB) — 538KB
• ino-20240331_pre.xml (EX-101.PRE) — 369KB
• ino-20240331_htm.xml (XML) — 690KB

Financial Information

Part I. Financial Information 1

Financial Statements

Item 1. Financial Statements 1 a) Condensed Consolidated Balance Sheets 2 b) Condensed Consolidated Statements of Operations 3 c) Condensed Consolidated Statements of Comprehensive Loss 4 d) Condensed Consolidated Statements of Stockholders' Equity 5 e) Condensed Consolidated Statements of Cash Flows 6 f) Notes to Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 20

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 24

Controls and Procedures

Item 4. Controls and Procedures 25

Other Information

Part II. Other Information 26

Legal Proceedings

Item 1. Legal Proceedings 26

Risk Factors

Item 1A. Risk Factors 26

Other Information

Item 5. Other Information 53

Exhibits

Item 6. Exhibits 53

Signatures

Signatures 55 SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Item 1A. Risk Factors herein. These risk factors include, but are not limited to, the following: We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable. We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary device technology. We will need substantial additional capital to develop our DNA medicines and proprietary device technology, which may prove difficult or costly to obtain. None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products. DNA medicines are a novel approach to treating and preventing disease, and our CELLECTRA delivery devices are a novel approach to administering medicines, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop or our devices could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals. If we and the contract manufacturers upon whom we rely fail to produce our proprietary devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary devices and DNA medicine candidates. If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships w

Financial Information

Part I. Financial Information

Financial Statements

Item 1. Financial Statements 1 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2024 December 31, 2023 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 19,601,829 $ 14,310,862 Short-term investments 86,013,044 130,982,913 Accounts receivable from affiliated entities 2,551,082 2,405,228 Prepaid expenses and other current assets 3,517,081 5,393,665 Prepaid expenses and other current assets from affiliated entities — 20,432 Total current assets 111,683,036 153,113,100 Fixed assets, net 5,015,067 4,960,986 Investment in affiliated entity 2,654,269 2,780,287 Operating lease right-of-use assets 9,156,478 9,491,735 Other assets 605,315 605,315 Total assets $ 129,114,165 $ 170,951,423 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses $ 16,675,922 $ 19,847,744 Accounts payable and accrued expenses due to affiliated entity 1,525,079 1,070,519 Accrued clinical trial expenses 3,022,486 2,365,382 Operating lease liability 2,155,540 2,406,522 Grant funding liability — 87,489 Grant funding liability from affiliated entity 21,918 21,918 Convertible senior notes — 16,770,654 Total current liabilities 23,400,945 42,570,228 Operating lease liability, net of current portion 11,271,257 11,032,066 Total liabilities 34,672,202 53,602,294 Stockholders' equity: Preferred stock — — Common stock 23,370 22,792 Additional paid-in capital 1,748,529,814 1,740,954,074 Accumulated deficit ( 1,653,435,007 ) ( 1,622,965,136 ) Accumulated other comprehensive loss ( 676,214 ) ( 662,601 ) Total Inovio Pharmaceuticals, Inc. stockholders' equity 94,441,963 117,349,129 Total liabilities and stockholders' equity $ 129,114,165 $ 170,951,423 See accompanying notes to unaudited condensed consolidated financial statements. 2 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended March 31, 2024 2023 Revenue from col

View Full Filing

View this 10-Q filing on SEC EDGAR